千金药业
(600479)
| 流通市值：44.78亿 | | | 总市值：44.78亿 |
| 流通股本：4.19亿 | | | 总股本：4.19亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,817,998,691.42 | 1,005,023,395.38 | 3,629,804,492.14 | 2,714,645,993.63 |
| 营业收入 | 1,817,998,691.42 | 1,005,023,395.38 | 3,629,804,492.14 | 2,714,645,993.63 |
| 二、营业总成本 | 1,636,266,894.81 | 922,900,905.5 | 3,317,463,364.57 | 2,475,132,343.8 |
| 营业成本 | 909,585,978.69 | 530,331,604.73 | 1,946,338,663.18 | 1,464,599,086.37 |
| 税金及附加 | 20,548,964.16 | 10,793,751.45 | 38,288,394.09 | 28,518,550.15 |
| 销售费用 | 473,367,807.23 | 254,595,958.22 | 849,485,024.18 | 656,039,950.54 |
| 管理费用 | 133,372,368.57 | 65,375,218.16 | 290,207,399.17 | 195,171,032.54 |
| 研发费用 | 104,183,648.41 | 61,461,708.51 | 220,204,530.81 | 144,395,569.53 |
| 财务费用 | -4,791,872.25 | 342,664.43 | -27,060,646.86 | -13,591,845.33 |
| 其中:利息费用 | 36,566.67 | 21,000 | 1,114,983.71 | 1,645,932.42 |
| 其中:利息收入 | 8,344,887.26 | 1,744,875.55 | 35,532,015.16 | 18,890,712.67 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,372,771.77 | 1,059,631.13 | 634,598.12 | -1,009,742.23 |
| 加:投资收益 | 18,803,638.62 | 6,059,608.71 | 15,582,312.28 | 2,419,826.5 |
| 资产处置收益 | 8,827.08 | - | 497,372.67 | - |
| 资产减值损失(新) | -2,038,165.9 | 88,844.47 | -7,823,288.98 | -1,996,475.41 |
| 信用减值损失(新) | -10,132,100.74 | -11,951,166.47 | -4,848,760.54 | -10,262,645.86 |
| 其他收益 | 5,547,761.33 | 2,659,204.94 | 15,727,291.07 | 11,925,242.84 |
| 四、营业利润 | 195,294,528.77 | 80,038,612.66 | 332,110,652.19 | 240,589,855.67 |
| 加:营业外收入 | 231,336.25 | 37,752.55 | 5,359,437.62 | 2,132,361.67 |
| 减:营业外支出 | 1,153,527.51 | 605,377.84 | 2,162,515.78 | 1,153,783.95 |
| 五、利润总额 | 194,372,337.51 | 79,470,987.37 | 335,307,574.03 | 241,568,433.39 |
| 减:所得税费用 | 20,336,376.12 | 7,151,983.21 | 32,698,873.02 | 28,203,388.52 |
| 六、净利润 | 174,035,961.39 | 72,319,004.16 | 302,608,701.01 | 213,365,044.87 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 174,035,961.39 | 72,319,004.16 | 302,608,701.01 | 213,365,044.87 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 127,725,142.44 | 53,155,316.53 | 230,756,619.25 | 168,076,563.28 |
| 少数股东损益 | 46,310,818.95 | 19,163,687.63 | 71,852,081.76 | 45,288,481.59 |
| 扣除非经常损益后的净利润 | 117,897,726.27 | 47,761,529.1 | 218,815,693.34 | 161,958,435.55 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.3 | 0.13 | 0.56 | 0.4 |
| (二)稀释每股收益 | 0.3 | 0.13 | 0.56 | 0.4 |
| 八、其他综合收益 | 524,144.56 | - | -13,947.49 | -75,373.07 |
| 归属于母公司股东的其他综合收益 | 524,144.56 | - | -13,947.49 | -75,373.07 |
| 九、综合收益总额 | 174,560,105.95 | 72,319,004.16 | 302,594,753.52 | 213,289,671.8 |
| 归属于母公司股东的综合收益总额 | 128,249,287 | 53,155,316.53 | 230,742,671.76 | 168,001,190.21 |
| 归属于少数股东的综合收益总额 | 46,310,818.95 | 19,163,687.63 | 71,852,081.76 | 45,288,481.59 |
| 公告日期 | 2025-08-30 | 2025-04-29 | 2025-04-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |